Cerebral ischemia and neuroregeneration

Neural Regen Res. 2018 Mar;13(3):373-385. doi: 10.4103/1673-5374.228711.

Abstract

Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies against stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

Keywords: cerebral ischemia; fatty acids; melatonin; neuromodulation therapy; pifithrin-α; protein kinase C; resveratrol; stem cell; sympathetic nervous system; traditional Chinese therapies.

Publication types

  • Review